These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

761 related items for PubMed ID: 16449339

  • 1. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.
    Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, Palermo L, Black DM.
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1370-5. PubMed ID: 16449339
    [Abstract] [Full Text] [Related]

  • 2. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis.
    Lane NE, Sanchez S, Genant HK, Jenkins DK, Arnaud CD.
    Osteoporos Int; 2000 Apr; 11(5):434-42. PubMed ID: 10912846
    [Abstract] [Full Text] [Related]

  • 3. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
    Bonnick S, De Villiers T, Odio A, Palacios S, Chapurlat R, DaSilva C, Scott BB, Le Bailly De Tilleghem C, Leung AT, Gurner D.
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
    [Abstract] [Full Text] [Related]

  • 4. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
    Fitzpatrick LA, Dabrowski CE, Cicconetti G, Gordon DN, Papapoulos S, Bone HG, Bilezikian JP.
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2441-9. PubMed ID: 21593114
    [Abstract] [Full Text] [Related]

  • 5. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
    Brixen K, Chapurlat R, Cheung AM, Keaveny TM, Fuerst T, Engelke K, Recker R, Dardzinski B, Verbruggen N, Ather S, Rosenberg E, de Papp AE.
    J Clin Endocrinol Metab; 2013 Feb; 98(2):571-80. PubMed ID: 23337728
    [Abstract] [Full Text] [Related]

  • 6. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

  • 7. Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling.
    Black DM, Bouxsein ML, Palermo L, McGowan JA, Newitt DC, Rosen E, Majumdar S, Rosen CJ, PTH Once-Weekly Research (POWR) Group.
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2166-72. PubMed ID: 18349061
    [Abstract] [Full Text] [Related]

  • 8. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial.
    Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD.
    J Bone Miner Res; 2000 May; 15(5):944-51. PubMed ID: 10804025
    [Abstract] [Full Text] [Related]

  • 9. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.
    Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ.
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2129-34. PubMed ID: 10852440
    [Abstract] [Full Text] [Related]

  • 10. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, Taves DH, Drost D.
    J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
    [Abstract] [Full Text] [Related]

  • 11. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 12. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
    Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ, PaTH Study Investigators.
    N Engl J Med; 2003 Sep 25; 349(13):1207-15. PubMed ID: 14500804
    [Abstract] [Full Text] [Related]

  • 13. Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate.
    Watts NB, Jenkins DK, Visor JM, Casal DC, Geusens P.
    Osteoporos Int; 2001 Sep 25; 12(4):279-88. PubMed ID: 11420777
    [Abstract] [Full Text] [Related]

  • 14. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM, Fracture Intervention Trial Long-Term Extension Research Group.
    J Bone Miner Res; 2004 Aug 25; 19(8):1259-69. PubMed ID: 15231012
    [Abstract] [Full Text] [Related]

  • 15. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.
    J Bone Miner Res; 1998 Sep 25; 13(9):1431-8. PubMed ID: 9738515
    [Abstract] [Full Text] [Related]

  • 16. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
    Kim SW, Park DJ, Park KS, Kim SY, Cho BY, Lee HK, Shin CS.
    Endocr J; 2005 Dec 25; 52(6):667-74. PubMed ID: 16410657
    [Abstract] [Full Text] [Related]

  • 17. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J.
    J Clin Endocrinol Metab; 2008 Jun 25; 93(6):2149-57. PubMed ID: 18381571
    [Abstract] [Full Text] [Related]

  • 18. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar 25; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 19. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.
    Lewiecki EM, Keaveny TM, Kopperdahl DL, Genant HK, Engelke K, Fuerst T, Kivitz A, Davies RY, Fitzpatrick LA.
    J Clin Endocrinol Metab; 2009 Jan 25; 94(1):171-80. PubMed ID: 18840641
    [Abstract] [Full Text] [Related]

  • 20. Treatment of postmenopausal women with osteoporosis with PTH(1-84) for 36 months: treatment extension study.
    Zanchetta JR, Bogado CE, Cisari C, Aslanidis S, Greisen H, Fox J, Lems W.
    Curr Med Res Opin; 2010 Nov 25; 26(11):2627-33. PubMed ID: 20923256
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.